‘So many relationships in the room’: Participant perspectives on the affordances and challenges of co‐therapy in psychedelic assisted therapy [PDF]
Abstract Objectives Psychedelic‐assisted therapy (PAT) frequently utilises a “cotherapy” model, in which two therapists jointly support participants throughout dosing and psychotherapy sessions. While common in clinical trials, participant experiences of cotherapy remain underexplored.
Rachel Ham +3 more
wiley +2 more sources
Psychedelic assisted psychotherapy (2020–2025): a scoping review of clinical evidence, mechanisms, safety, and ethics [PDF]
BackgroundClinical research on psychedelic-assisted therapy (PAT) has expanded substantially in recent years, particularly for post-traumatic stress disorder (PTSD) and depressive disorders.
Nasiru Mohammed Abdullahi +23 more
doaj +2 more sources
Psychedelics in Mental Health: Opportunities and Challenges [PDF]
ABSTRACT Psychedelic and substance‐assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment‐resistant depression, post‐traumatic stress disorder, and substance use disorders.
Lena K. L. Oestreich, Nathalie M. Rieser
wiley +2 more sources
Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica [PDF]
We report two case studies that examine the therapeutic potential of structured psilocybin-containing mushroom biomass regimens administered within a clinical framework, evaluating their impact on mental health outcomes as well as associated somatic ...
Caitlyn Hanna Sams +6 more
doaj +2 more sources
Therapeutic use of psilocybin: Practical considerations for dosing and administration
The interest in psilocybin as a therapeutic approach has grown exponentially in recent years. Despite increasing access, there remains a lack of practical guidance on the topic for health care professionals.
Caroline A. MacCallum +3 more
doaj +1 more source
Introduction During the last decade there has been a resurgence of interest on the use of psychedelics as novel treatments for mental disorders, including treatment-resistant depression (TRD). Psilocybin, the chemical component of “magic mushrooms”, has
M. I. Husain +6 more
doaj +1 more source
Will psilocybin lose its magic in the clinical setting?
Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what ...
Caroline Hayes +2 more
doaj +1 more source
Research on the clinical applications of psychedelic-assisted psychotherapy has demonstrated promising early results for treatment of alcohol dependence.
Elizabeth M. Nielson +3 more
doaj +1 more source
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation ...
Antonio Munafò +5 more
doaj +1 more source
Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience [PDF]
Attachment insecurity is determined early in life, is a risk factor for psychopathology, and can be measured on two separate continuous dimensions: attachment anxiety and attachment avoidance.
Stauffer, Christopher S +7 more
core +1 more source

